TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26851940

Group type: EXPERIMENTAL
Intervention: Parents' MVPA on weekdays
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Parents' MVPA on weekend days
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Children's MVPA on weekdays
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Children's MVPA on weekend days
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Total counts per minute for children on weekdays
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Total counts per minute for children on weekend days
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Correlation of total counts per minute on weekend days
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Correlation of total counts per minute on weekdays
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Correlation of parents and children for MVPA on weekend days
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Correlation of parents and children for MVPA on weekdays
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Correlation of sedentary time on weekend days
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Correlation of sedentary time on weekdays
Number of subjects: 199
Study: 26852132

Group type: EXPERIMENTAL
Intervention: Anthracycline treatment (specifically epirubicin)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Histone deacetylase small-molecule inhibitors
Number of subjects: 4

Group type: COMPARATOR
Intervention: Epirubicin-resistant cells
Number of subjects: 4
Study: 26852181

Group type: EXPERIMENTAL
Intervention: Pacifier use (non-nutritive sucking)
Number of subjects: 30
Study: 26852658

Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 0
Study: 26853180

Group type: EXPERIMENTAL
Intervention: ustekinumab
Number of subjects: 2076
Study: 26853249

Group type: EXPERIMENTAL
Intervention: Pre-hospital care (PHC)
Number of subjects: 6123

Group type: EXPERIMENTAL
Intervention: Pre-hospital medication (PHM)
Number of subjects: 6123

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 6123

Group type: EXPERIMENTAL
Intervention: Thrombolytics
Number of subjects: 6123

Group type: EXPERIMENTAL
Intervention: Time from symptoms onset to ECG
Number of subjects: 6123

Group type: EXPERIMENTAL
Intervention: First medical attention (FMA)
Number of subjects: 6123

Group type: EXPERIMENTAL
Intervention: ECG within 10 minutes of FMA
Number of subjects: 6123
Study: 26853647

Group type: EXPERIMENTAL
Intervention: AIEOP-BFM protocols (2000 and 2009)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: AIEOP-BFM 2009 protocol
Number of subjects: 49

Group type: COMPARATOR
Intervention: AIEOP-BFM protocols
Number of subjects: 49
Study: 26854432

Group type: EXPERIMENTAL
Intervention: Emerging therapies targeting castration-resistant prostate cancer
Number of subjects: 0
Study: 26854578

Group type: EXPERIMENTAL
Intervention: Pregabalin (300, 600 mg/day or flexible)
Number of subjects: 2935

Group type: EXPERIMENTAL
Intervention: Pregabalin (all doses)
Number of subjects: 2935

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 2935

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2935
Study: 26854928

Group type: EXPERIMENTAL
Intervention: Sequences of 2-millisecond light flashes (n = 31) with different interstimulus intervals (ISIs; ranging from 2.5 to 240 seconds)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Continuous light (n = 8)
Number of subjects: 39
Study: 26855099

Group type: EXPERIMENTAL
Intervention: 100% cervical effacement in spontaneous labor
Number of subjects: 3902

Group type: EXPERIMENTAL
Intervention: 100% cervical effacement with oxytocin
Number of subjects: 3902
Study: 26855613

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV) for more than 48 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nursing-sensitive outcomes (NSO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICU stressors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other clinical variables
Number of subjects: 0
Study: 26855665

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed guar gum (PHGG) 6 g/day
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 26855682

Group type: EXPERIMENTAL
Intervention: Mavoglurant (25, 50, or 100 mg BID)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Mavoglurant (100 mg BID or highest tolerated dose)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 26856824

Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Post-dialysis dolutegravir concentrations
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dosage adjustments
Number of subjects: 5
Study: 26857191

Group type: EXPERIMENTAL
Intervention: Smartphones in standby mode directly over the ICD generator
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Smartphones in dialing and operating modes directly over the generator casing and over the parasternal region
Number of subjects: 63
Study: 26857558

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 2500
Study: 26857702

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus oxaliplatin/capecitabine
Number of subjects: 51
Study: 26857907

Group type: EXPERIMENTAL
Intervention: Selective electrophysiologically guided atrial substrate modification after circumferential pulmonary vein isolation and cavotricuspid isthmus ablation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Stepwise approach (historical control group)
Number of subjects: 86
Study: 26858124

Group type: EXPERIMENTAL
Intervention: CD3/CD28 costimulated umbilical cord blood T cells (10^5 cells/kg)
Number of subjects: 4
Study: 26858336

Group type: EXPERIMENTAL
Intervention: NEOD001 (24 mg/kg)
Number of subjects: 27
Study: 26858840

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: 1000 IU/d of vitamin D3
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: 2000 IU/d of vitamin D3
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: 4000 IU/d of vitamin D3
Number of subjects: 328
Study: 26859094

Group type: EXPERIMENTAL
Intervention: Additional protein fortification
Number of subjects: 152
Study: 26859103

Group type: EXPERIMENTAL
Intervention: AHSCT (Autologous Hematopoietic Stem Cell Transplantation) protocol using fludarabine in an outpatient setting
Number of subjects: 16
Study: 26859538

Group type: EXPERIMENTAL
Intervention: Once-daily tiotropium 5 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twice-daily tiotropium 2.5 μg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of both regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total tiotropium exposure
Number of subjects: 0
Study: 26859761

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG-ATCC 53103 (LGG) treatment for 28 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Post-treatment (Day 56)
Number of subjects: 11
Study: 26859866

Group type: EXPERIMENTAL
Intervention: EMR
Number of subjects: 203
Study: 26860632

Group type: EXPERIMENTAL
Intervention: bevacizumab plus tandutinib
Number of subjects: 41
Study: 26860741

Group type: EXPERIMENTAL
Intervention: Digital games for cognitive functioning and general well-being
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study: 26861157

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFAs)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Children with ADHD
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Lower blood levels of PUFA
Number of subjects: 73
Study: 26861458

Group type: EXPERIMENTAL
Intervention: CEA TCB
Number of subjects: 110
Study: 26861602

Group type: EXPERIMENTAL
Intervention: Everolimus added to trastuzumab and paclitaxel as first-line therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (trastuzumab and paclitaxel without everolimus)
Number of subjects: 0
Study: 26861666

Group type: EXPERIMENTAL
Intervention: Parecoxib (Group D)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 90
Study: 26861740

Group type: EXPERIMENTAL
Intervention: Sorafenib (200mg qd titrated to 400mg BID) with infusional 5-FU (225 mg/m(2)/24h) and radiation (28 fractions at 1.8 Gy)
Number of subjects: 17
Study: 26861867

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 2113

Group type: COMPARATOR
Intervention: ICS ± LABA
Number of subjects: 2113

Group type: EXPERIMENTAL
Intervention: Tiotropium (in subjects without comorbid asthma)
Number of subjects: 2113

Group type: COMPARATOR
Intervention: ICS ± LABA (in subjects without comorbid asthma)
Number of subjects: 2113
Study: 26861905

Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg daily for 2 years
Number of subjects: 37
Study: 26861921

Group type: EXPERIMENTAL
Intervention: 75 μg nonaqueous glucagon
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 150 μg nonaqueous glucagon
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 μg nonaqueous glucagon
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Post-insulin administration with 75 μg glucagon
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Post-insulin administration with 150 μg glucagon
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Post-insulin administration with 300 μg glucagon
Number of subjects: 12
Study: 26861943

Group type: EXPERIMENTAL
Intervention: Confirmed clinical malaria (CCM)
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Asymptomatic parasitaemia (AP)
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Positive blood smears
Number of subjects: 1640
Study: 26863635

Group type: EXPERIMENTAL
Intervention: Immunotherapy with histamine dihydrochloride and low-dose interleukin-2
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Presence of CD8+ T cells with specificity for leukemia-associated antigens
Number of subjects: 84
Study: 26864153

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin (12-week duration)
Number of subjects: 129
Study: 26864194

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg·kg(-1)
Number of subjects: 36
Study: 26864236

Group type: EXPERIMENTAL
Intervention: Intensive glycemic therapy
Number of subjects: 216

Group type: COMPARATOR
Intervention: Conventional glycemic therapy
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: LW-1
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: SIF and CLF
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: SIF and LW-1
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: LW-1 and CLF
Number of subjects: 216
Study: 26864355

Group type: EXPERIMENTAL
Intervention: TMAO and choline concentrations at least the median (n = 83)
Number of subjects: 283

Group type: COMPARATOR
Intervention: TMAO and choline concentrations less than the median (n = 82)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Diabetes presence
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Sex (male)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Sex (female)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Overall group analysis
Number of subjects: 283
Study: 26864370

Group type: EXPERIMENTAL
Intervention: Constant mean energy intake for 92.2 ± 7.9 days
Number of subjects: 13
Study: 26864794

Group type: EXPERIMENTAL
Intervention: Strenuous exercise (amateur cycling race)
Number of subjects: 92
Study: 26865277

Group type: EXPERIMENTAL
Intervention: miR-92a mimics
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: miR-92a inhibitors
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Endogenous miR-92a expression
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Integrative model predictions
Number of subjects: 138
Study: 26865594

Group type: EXPERIMENTAL
Intervention: 4-IM (3-dose IM priming with a single booster at 42 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-IM (3-dose IM priming with boosters at 18 and 42 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7-IM (3-dose IM priming with boosters at 12, 18, 30, and 42 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8-SQ (licensed priming series of 6 doses with two annual boosters administered subcutaneously)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8-IM (licensed priming series of 6 doses with two annual boosters administered intramuscularly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo control
Number of subjects: 0
Study: 26865869

Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration training (6 Hz, Noise 4 SR-WBV)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham / 1 Hz, Noise 1 SR-WBV
Number of subjects: 9
Study: 26866015

Group type: EXPERIMENTAL
Intervention: AFFITOPE® AD02 (amyloid-beta-targeting vaccine)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Adapted ADAS-cog scale
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Adapted ADCS-ADL scale
Number of subjects: 318

Group type: COMPARATOR
Intervention: Traditional scales
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Composite scales
Number of subjects: 318
Study: 26866579

Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES) results disclosure
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Oncologists' experience with germ-line tests
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Patients' genetic knowledge
Number of subjects: 167
Study: 26867033

Group type: EXPERIMENTAL
Intervention: Biomarker models developed with combined traditional and novel biomarkers
Number of subjects: 140

Group type: COMPARATOR
Intervention: Traditional clinical markers alone
Number of subjects: 140
Study: 26867061

Group type: EXPERIMENTAL
Intervention: Bilateral renal denervation (RDN) performed with a single electrode Symplicity catheter.
Number of subjects: 1
Study: 26867073

Group type: EXPERIMENTAL
Intervention: Trait anxiety in women
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High trait anxiety in women
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Low trait anxiety in women
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: State anxiety in men
Number of subjects: 55
Study: 26867206

Group type: EXPERIMENTAL
Intervention: Pegylated interferon-α2a ± ribavirin (ATAHC II)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Pegylated interferon-α2a, ribavirin and telaprevir (DARE-C I)
Number of subjects: 82
Study: 26867531

Group type: EXPERIMENTAL
Intervention: Rhinitis Control Scoring System (RCSS)
Number of subjects: 50
Study: 26868015

Group type: EXPERIMENTAL
Intervention: MRI T2 mapping
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: dGEMRIC
Number of subjects: 28
Study: 26868114

Group type: EXPERIMENTAL
Intervention: DAIR treatment
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: DAIR-only
Number of subjects: 35
Study: 26868433

Group type: EXPERIMENTAL
Intervention: Genetic variation at IRS1 locus (rs4675095-T)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Genetic variation at ENPP1 locus (rs4897549-A)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Genetic variation at TRIB3 locus (rs7265169-A)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Genetic variation at ENPP1 locus (rs858340-G)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity assessment via euglycaemic insulin clamp
Number of subjects: 597
Study: 26868693

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 249
Study: 26868955

Group type: EXPERIMENTAL
Intervention: Linear processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semicompressive scheme
Number of subjects: 0

Group type: COMPARATOR
Intervention: NAL-NL2 prescription rule
Number of subjects: 0
Study: 26869376

Group type: EXPERIMENTAL
Intervention: 5 μg dose of glycoconjugate GBS vaccine (serotypes Ia, Ib, and III, with CRM197) administered intramuscularly at 24-35 weeks' gestation.
Number of subjects: 270
Study: 26869384

Group type: EXPERIMENTAL
Intervention: High adherence to the DASH diet
Number of subjects: 74404
Study: 26869472

Group type: EXPERIMENTAL
Intervention: Angioplasty and self-expanding stents
Number of subjects: 100
Study: 26869532

Group type: EXPERIMENTAL
Intervention: Dengue IgG-antibodies
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Chikungunya IgG-antibodies
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Dengue incidence
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Chikungunya incidence
Number of subjects: 162
Study: 26869630

Group type: EXPERIMENTAL
Intervention: Haplo-cord transplant
Number of subjects: 290
Study: 26869631

Group type: EXPERIMENTAL
Intervention: Lineage-specific chimerism testing
Number of subjects: 162
Study: 26869674

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26869675

Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 245

Group type: COMPARATOR
Intervention: No asthma
Number of subjects: 245
Study: 26869676

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26869690

Group type: EXPERIMENTAL
Intervention: Ribavirin + Abacavir (300 mg orally every 12 h)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ribavirin alone (weight-based dosing)
Number of subjects: 26
Study: 26870152

Group type: EXPERIMENTAL
Intervention: Lower dose of multivitamins/minerals
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Higher dose of multivitamins/minerals
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Chronic supplementation (8 weeks) with multivitamins/minerals
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 26870387

Group type: EXPERIMENTAL
Intervention: Increased IVST in patients with ATTR
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Absence of restrictive pattern and low voltage
Number of subjects: 425
Study: 26870733

Group type: EXPERIMENTAL
Intervention: Triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV, and promethazine 25 mg IV
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Triple therapy of palonosetron, dexamethasone, and promethazine
Number of subjects: 40
Study: 26870801

Group type: EXPERIMENTAL
Intervention: Oral polio vaccine
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine
Number of subjects: 700

Group type: COMPARATOR
Intervention: Tetanus vaccine
Number of subjects: 700

Group type: COMPARATOR
Intervention: Haemophilus influenzae type b vaccine
Number of subjects: 700

Group type: COMPARATOR
Intervention: Diphtheria vaccine
Number of subjects: 700

Group type: COMPARATOR
Intervention: Measles vaccine
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Biomarkers of systemic inflammation and maternal health measures
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Rotarix® IgA positive individuals
Number of subjects: 700
Study: 26871197

Group type: EXPERIMENTAL
Intervention: Low-dose imatinib plus nilotinib
Number of subjects: 10
Study: 26871248

Group type: EXPERIMENTAL
Intervention: Recorded music-listening intervention for 3 months
Number of subjects: 150
Study: 26871769

Group type: EXPERIMENTAL
Intervention: LncPPARδ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of LncPPARδ and risk factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LncPPARδ silencing
Number of subjects: 0
Study: 26871943

Group type: EXPERIMENTAL
Intervention: Integration of alcohol treatment into TB treatment
Number of subjects: 196

Group type: COMPARATOR
Intervention: Incarceration history
Number of subjects: 196

Group type: COMPARATOR
Intervention: Age under 41
Number of subjects: 196

Group type: COMPARATOR
Intervention: Drug addiction
Number of subjects: 196

Group type: COMPARATOR
Intervention: History of a sexually transmitted disease (STD)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Low social capital
Number of subjects: 196

Group type: COMPARATOR
Intervention: Heavier alcohol use
Number of subjects: 196
Study: 26872002

Group type: EXPERIMENTAL
Intervention: Ambassadorship application
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Pre-existing friendships
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Surplus of personal resources
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Non-friend classmates with surplus resources
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Pre-existing friendship with limited resources
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Non-friend classmates with limited resources
Number of subjects: 221
Study: 26872154

Group type: EXPERIMENTAL
Intervention: Low 25-hydroxyvitamin D
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Low 25-hydroxyvitamin D with TMEM 16J rs7111432-AA
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Low 25-hydroxyvitamin D with PKP3 rs10902158-GG
Number of subjects: 466
Study: 26872720

Group type: EXPERIMENTAL
Intervention: LNG-IUS 8 (total content 13.5mg, average release rate 8μg/24h over the first year)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: LNG-IUS 8
Number of subjects: 304
Study: 26873642

Group type: EXPERIMENTAL
Intervention: Alisertib 50 mg orally BID for 7 days with 14 days rest until disease progression
Number of subjects: 22
Study: 26873687

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy in women
Number of subjects: 5539

Group type: COMPARATOR
Intervention: All ICD recipients
Number of subjects: 5539
Study: 26873693

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 80
Study: 26874378

Group type: EXPERIMENTAL
Intervention: Breathing reserve
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Percent predicted oxygen uptake efficiency slope (OUES)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: VO2/WR slope
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: VO2 at the anaerobic threshold (AT)
Number of subjects: 73
Study: 26874395

Group type: EXPERIMENTAL
Intervention: Severely high predischarge BP group
Number of subjects: 146

Group type: COMPARATOR
Intervention: Moderately high predischarge BP group
Number of subjects: 146
Study: 26874895

Group type: EXPERIMENTAL
Intervention: Transcutaneous PCO2 (PtcCO2) monitoring
Number of subjects: 67
Study: 26875023

Group type: EXPERIMENTAL
Intervention: Parent/caregiver-reported family dinner frequency measures
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Child-reported family dinner frequency measures
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Family dinner frequency measures
Number of subjects: 160
Study: 26876245

Group type: EXPERIMENTAL
Intervention: Deferasirox (20 mg·kg(-1)·d(-1))
Number of subjects: 64
Study: 26876309

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg daily
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215